Bissan Al-Lazikani
Bissan Al-Lazikani
Professor, Genomic Medicine; Director Therapeutics Data Science
Verified email at
Cited by
Cited by
How many drug targets are there?
JP Overington, B Al-Lazikani, AL Hopkins
Nature reviews Drug discovery 5 (12), 993-996, 2006
ChEMBL: a large-scale bioactivity database for drug discovery
A Gaulton, LJ Bellis, AP Bento, J Chambers, M Davies, A Hersey, Y Light, ...
Nucleic acids research 40 (D1), D1100-D1107, 2012
A comprehensive map of molecular drug targets
R Santos, O Ursu, A Gaulton, AP Bento, RS Donadi, CG Bologa, ...
Nature reviews Drug discovery 16 (1), 19-34, 2017
The genome of the blood fluke Schistosoma mansoni
M Berriman, BJ Haas, PT LoVerde, RA Wilson, GP Dillon, GC Cerqueira, ...
Nature 460 (7253), 352-358, 2009
Standard conformations for the canonical structures of immunoglobulins
B Al-Lazikani, AM Lesk, C Chothia
Journal of molecular biology 273 (4), 927-948, 1997
Combinatorial drug therapy for cancer in the post-genomic era
B Al-Lazikani, U Banerji, P Workman
Nature biotechnology 30 (7), 679-692, 2012
Therapeutic opportunities within the DNA damage response
LH Pearl, AC Schierz, SE Ward, B Al-Lazikani, FMG Pearl
Nature Reviews Cancer 15 (3), 166-180, 2015
Defective acute inflammation in Crohn's disease: a clinical investigation
DJB Marks, MWN Harbord, R MacAllister, FZ Rahman, J Young, ...
The Lancet 367 (9511), 668-678, 2006
Genomic-scale prioritization of drug targets: the TDR Targets database
F AgŁero, B Al-Lazikani, M Aslett, M Berriman, FS Buckner, RK Campbell, ...
Nature reviews Drug discovery 7 (11), 900-907, 2008
Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance
D Gonzalez de Castro, PA Clarke, B Al‐Lazikani, P Workman
Clinical Pharmacology & Therapeutics 93 (3), 252-259, 2013
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
DC Wedge, G Gundem, T Mitchell, DJ Woodcock, I Martincorena, M Ghori, ...
Nature genetics 50 (5), 682-692, 2018
Protein structure prediction
B Al-Lazikani, J Jung, Z Xiang, B Honig
Current opinion in chemical biology 5 (1), 51-56, 2001
Objective assessment of cancer genes for drug discovery
MN Patel, MD Halling-Brown, JE Tym, P Workman, B Al-Lazikani
Nature reviews Drug discovery 12 (1), 35-50, 2013
Drug discovery in advanced prostate cancer: translating biology into therapy
TA Yap, AD Smith, R Ferraldeschi, B Al-Lazikani, P Workman, ...
Nature reviews Drug discovery 15 (10), 699-718, 2016
Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation
C Abad-Zapatero, O Perišić, J Wass, AP Bento, J Overington, ...
Drug discovery today 15 (19-20), 804-811, 2010
Large-scale profiling of kinase dependencies in cancer cell lines
J Campbell, CJ Ryan, R Brough, I Bajrami, HN Pemberton, IY Chong, ...
Cell reports 14 (10), 2490-2501, 2016
canSAR: an updated cancer research and drug discovery knowledgebase
JE Tym, C Mitsopoulos, EA Coker, P Razaz, AC Schierz, AA Antolin, ...
Nucleic acids research 44 (D1), D938-D943, 2016
Minimum information about a bioactive entity (MIABE)
S Orchard, B Al-Lazikani, S Bryant, D Clark, E Calder, I Dix, O Engkvist, ...
Nature reviews Drug discovery 10 (9), 661-669, 2011
canSAR: updated cancer research and drug discovery knowledgebase
KC Bulusu, JE Tym, EA Coker, AC Schierz, B Al-Lazikani
Nucleic acids research 42 (D1), D1040-D1047, 2014
JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells
ZS Walters, B Villarejo-Balcells, D Olmos, TWS Buist, E Missiaglia, ...
Oncogene 33 (9), 1148-1157, 2014
The system can't perform the operation now. Try again later.
Articles 1–20